Elmind Capital
Elmind Capital reported 30 stocks worth $404M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CLDX (8.9%), LEGN (7.7%) and SNDX (7.5%). Compared with Q2 2026, the fund added to CLDX, LEGN and AMLX, trimmed SNDX, COGT and PCVX and sold out of INSM, PTGX and WVE.
Latest filing: what Elmind Capital did in Q3 2026
vs Q2 2026None
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() CLDX Celldex Therapeutics Inc | $36M | 8.9% | 1.1M | +120K (+12%) | 4 of 4 | |
| 2 | ![]() LEGN Legend Biotech Corp | $31.2M | 7.7% | 1.6M | +999K (+175%) | 2 of 4 | |
| 3 | ![]() SNDX Syndax Pharmaceuticals Inc | $30.2M | 7.5% | 1.6M | −250K (−13%) | 4 of 4 | |
| 4 | ![]() COGT Cogent Biosciences Inc | $27.8M | 6.9% | 867K | −304K (−26%) | 4 of 4 | |
| 5 | ![]() RLAY Relay Therapeutics Inc | $26.4M | 6.5% | 1.5M | No change | 4 of 4 | |
| 6 | ![]() AMLX Amylyx Pharmaceuticals Inc | $26M | 6.5% | 895K | +783K (+699%) | 4 of 4 | |
| 7 | ![]() VRDN Viridian Therapeutics Inc | $25.2M | 6.3% | 1.2M | +240K (+24%) | 4 of 4 | |
| 8 | ![]() PCVX Vaxcyte Inc | $21.2M | 5.3% | 372K | −80K (−18%) | 4 of 4 | |
| 9 | ![]() URGN Urogen Pharma Ltd | $20M | 4.9% | 491K | +371K (+309%) | 4 of 4 | |
| 10 | ![]() TVTX Travere Therapeutics Inc | $19M | 4.7% | 323K | +30K (+10%) | 4 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Elmind Capital 13F FAQ
What does Elmind Capital own?
Elmind Capital reported 30 stocks worth $404M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CLDX (8.9%), LEGN (7.7%) and SNDX (7.5%). The table above lists every position in the filing (the top 10 without an account).
What did Elmind Capital buy and sell in Q3 2026?
Compared with Q2 2026: 0 new positions, 11 added to, 5 trimmed and 5 sold out. It sold all of INSM, PTGX and WVE.
When will Elmind Capital file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Elmind Capital's portfolio worth?
The Q3 2026 filing reports $404M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

















